Azenta Life Sciences (Nasdaq: AZTA) provides end-to-end infrastructure for managing biological samples and genomic data. Its core offering spans automated cryogenic and ultra-low temperature storage, cold-chain logistics, and laboratory informatics - combined with genomic sequencing services delivered through its GENEWIZ brand. The integrated platform covers the full chain of custody for samples, from physical preservation through data generation, across global facilities.
The company's technical domains reflect the complexity of modern life sciences operations:
- Automated biorepositories and cryogenic storage operating at temperatures as low as -190°C
- Cold-chain logistics for temperature-controlled sample transport and handling
- Informatics platforms that maintain chain of custody across distributed, global facilities
- Genomic sequencing and multiomics services integrated with sample management workflows
Azenta manages over one billion biological samples worldwide and counts all 20 of the top 20 pharmaceutical and biotech companies among its customers. Its client base extends to research institutions and organisations working in cell and gene therapy development, clinical trials, and multiomics research.
The company is listed on Nasdaq under the ticker AZTA and operates across a global network of facilities, serving pharmaceutical and biotech organisations that require reliable, high-integrity management of irreplaceable biological materials.
